Gemphire Therapeutics Inc. (GEMP) EPS Estimated At $-0.72; DNO ASA (DTNOF) Sellers Increased By 34.46% Their Shorts

February 20, 2018 - By Linda Rogers

DNO ASA (OTCMKTS:DTNOF) had an increase of 34.46% in short interest. DTNOF’s SI was 5.84M shares in February as released by FINRA. Its up 34.46% from 4.34M shares previously. With 3,700 avg volume, 1578 days are for DNO ASA (OTCMKTS:DTNOF)’s short sellers to cover DTNOF’s short positions. It closed at $1.1 lastly. It is down 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report $-0.72 EPS on March, 21.They anticipate $0.06 EPS change or 7.69% from last quarter’s $-0.78 EPS. After having $-0.82 EPS previously, Gemphire Therapeutics Inc.’s analysts see -12.20% EPS growth. The stock increased 2.29% or $0.151 during the last trading session, reaching $6.751. About 27,064 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $93.00 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, August 30 by Jefferies. RBC Capital Markets initiated the shares of GEMP in report on Tuesday, August 30 with “Outperform” rating. Canaccord Genuity initiated the shares of GEMP in report on Tuesday, August 30 with “Buy” rating.

DNO ASA engages in the exploration, development, and production of gas and oil primarily in the Middle East and North Africa. The company has market cap of $1.30 billion. The Company’s flagship project is the Tawke field that is located in the Kurdistan region. It has a 2.39 P/E ratio. The firm holds seven licenses in the Kurdistan region of Iraq, the Sultanate of Oman, the Tunisian Republic, the Republic of Yemen, and Somaliland.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>